Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) said company management will present at two investor conferences in November 2025: the UBS Global Healthcare Conference in Palm Beach Gardens, FL on November 10, 2025 at 2:45 p.m. ET, and the Jefferies Global Healthcare Conference in London on November 18, 2025 at 4:30 p.m. GMT.
Live audio webcasts of both presentations will be available via the company’s investor relations website at https://ir.amicusrx.com/events-and-presentations. Contact details for investor and media relations were provided.
Details
News Market Reaction – FOLD
On Oct 31, the day this news came out, FOLD closed 1.46% above the previous close.
Data tracked by StockTitan Argus for the Oct 31 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.
- 2025 UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10, 2025, at 2:45 p.m. ET
- Jefferies Global Healthcare Conference 2025 in London, U.K. on Tuesday, November 18, 2025, at 4:30 p.m. GMT
A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on LinkedIn.
CONTACT:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Brendan McEvoy
Executive Director, External Communications
bmcevoy@amicusrx.com
(609) 662-5005
FOLD–G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.